NCT01263769View on ClinicalTrials.gov

Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

February 28, 2021

Study Completion Date

June 5, 2023

Conditions
Kidney Cancer
Interventions
DRUG

Axitinib

Starting dose: 5 mg by mouth twice each day for 12 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER